Recurrent intracranial hemorrhage without brain metastasis after VEGFR TKI rechallenge in metastatic renal cell carcinoma: a case report and literature review - Scorecard - MDSpire
Advertisement
Recurrent intracranial hemorrhage without brain metastasis after VEGFR TKI rechallenge in metastatic renal cell carcinoma: a case report and literature review
Clinical Scorecard: Intracranial Hemorrhage Recurrence Following VEGFR TKI Rechallenge in Metastatic Renal Cell Carcinoma: A Case Study and Review of Existing Literature
At a Glance
Category
Detail
Condition
Key Mechanisms
VEGFR TKIs disrupt endothelial cell homeostasis, leading to hemorrhagic complications. [Source needed]
Target Population
Care Setting
Key Highlights
Intracranial hemorrhage is a rare but serious adverse effect of VEGFR TKIs.
Rechallenge with VEGFR TKIs after CNS hemorrhage requires careful consideration of risks.
A waiting period is essential before considering VEGFR TKI re-administration. [Source needed]
Guideline-Based Recommendations
Diagnosis
Monitor for neurological symptoms in patients receiving VEGFR TKIs. [Source needed]
Management
Consider surgical intervention for significant intracranial hemorrhage. [Source needed]
Monitoring & Follow-up
Regular imaging and clinical assessment post-VEGFR TKI therapy. [Source needed]
Risks
Increased risk of hemorrhagic events, particularly in patients with prior CNS hemorrhage. [Source needed]
Patient & Prescribing Data
Careful assessment of risks versus benefits is crucial before re-administering VEGFR TKIs. [Source needed]
Clinical Best Practices
Conduct thorough evaluations for potential bleeding risks before initiating VEGFR TKI therapy. [Source needed]
Implement a multidisciplinary approach for managing complications related to VEGFR TKIs. [Source needed]
